obesity drug news today glp-1 october 21 2025 Outlook for in 2025: more than a transition year The Age of Oral GLP-1s

Understanding variants in genes like GIPR and GLP1R reveals whether you're genetically predisposed to dramatic cholesterol improvements or modest gains, allowing PlexusDx providers to personalize your protocol and set realistic targets

Since the cost of these drugs can be prohibitive, these findings could have a major real-world impact, says Mitch Biermann, MD, PhD, an author of the study and an obesity medicine and internal medicine doctor at Scripps Clinic Carmel Valley in California

Microbial modulation of energy availability in the colon regulates intestinal transit

Your provider will discuss whether compounded therapy is appropriate for your goals and health profile during your consult

By week 9, approximately 85% of users report significant improvement in gastrointestinal symptoms

Ozempic (semaglutide) has dominated the GLP-1 market due to its early approval, strong efficacy in glycemic control, and weekly administration convenience